Skip to main content

Table 1 Baseline characteristics

From: MRI-guided percutaneous thermoablation in combination with hepatic resection as parenchyma-sparing approach in patients with primary and secondary hepatic malignancies: single center long-term experience

VariablesN (%)/mean ± SD
Age (years)62.8 ± 9.1
Patients31
Sex (m/f)21 (67.8%) / 10 (32.2%)
Number of tumors (ablated/resected)98 (42/56)
Tumor size of ablated lesions15.1 ± 7.6 mm
Tumor size of resected lesions28.7 ± 23.0 mm
Tumor entityHCC (n = 7)
iCCA (n = 1)
Metastases (n = 23)
 Colorectal carcinoma (n = 17)
  - Left sided (n = 13)
 - Right sided (n = 4)
 Uveal melanoma (n = 3)
 Malignant melanoma (n = 1)
 Breast cancer (n = 1)
 Neuroendocrine tumor (n = 1)
Concomitant liver cirrhosis5/31 (16.1%);
Child A: n = 3, Child B: n = 2
Liver function (serum levels):
 GOT/GPT (U/I)45.2 ± 39.0 / 47.5 ± 43.7
 Bilirubin (mg/dl)0.6 ± 0.3
 Quick-Test (%)96.6 ± 13.9
  1. HCC Hepatocellular carcinoma, iCCA Intrahepatic cholangiocarcinoma, TACE Transarterial chemoembolization